SCHEDULE 13G/A: BlackRock Amends Organon & Co. Stake, Disclosing 11.9% Beneficial Ownership

BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, revealing a beneficial ownership of 11.9% in Organon & Co.'s common stock as of March 31, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 4 to its Schedule 13G regarding its beneficial ownership in Organon & Co.
• As of March 31, 2025, BlackRock, Inc. beneficially owns 30,659,006 shares of Organon & Co. common stock.
• This represents 11.9% of the total outstanding common stock of Organon & Co.
• BlackRock holds sole voting power over 30,029,675 shares and sole dispositive power over 30,659,006 shares.
• The filing indicates that iShares Core S&P Small-Cap ETF, a BlackRock entity, holds more than 5% of the total outstanding common stock of Organon & Co.
• The filing was made by BlackRock, Inc. as a parent holding company, in accordance with Rule 13d-1(b).

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, indicating a passive investment. It contains no positive or negative performance-related information about the issuer, Organon & Co. The sentiment is neutral as it simply reports a stake.

Positives

• The disclosure of a significant 11.9% stake by a major institutional investor like BlackRock, Inc. may signal confidence in Organon & Co.'s long-term prospects.

Future Outlook

NA

Management Comments

• BlackRock, Inc. certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
• The securities were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

Schedule 13G filings are standard disclosures by institutional investors holding more than 5% of a company's stock, indicating a passive investment intent. BlackRock, as one of the world's largest asset managers, frequently appears in such filings across various industries, reflecting its broad investment mandates through its diverse funds and ETFs. This filing specifically highlights its significant stake in Organon & Co., a company operating in the healthcare/pharmaceutical sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, which can influence market perception and liquidity.
• Management: Awareness of a large passive investor, though BlackRock's stated intent is not to influence control.

Key Dates

Keywords

BlackRock, Organon & Co., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Pharmaceuticals, Healthcare, Asset Management, Equity Stake